Drug Development · asia
ONO-1110 misses endpoints in three pain trials; Ono still plans further research
After the primary endpoints were missed, subgroup and exploratory analyses offered leads for further research. Ono will focus ONO-1110 development on three pain conditions, while research in depression and social anxiety disorder will stop.
When a new pain drug fails a trial’s prespecified primary test, can subsequent signals of improvement support continued development? On October 29, Ono Pharmaceutical announced results from five Phase 2 clinical trials of its oral drug candidate ONO-1110: all three pain studies missed their primary endpoints, but the company still plans further research; the other two studies in psychiatric disorders showed no efficacy signals and will not advance.
ONO-1110 is an endocannabinoid modulator. Endocannabinoids are substances produced naturally by the human body that help regulate neurological functions, including pain and mood. Ono hopes to achieve pain relief by modulating this physiological mechanism, but whether this approach can translate into reliable clinical benefits still requires evidence from human trials.
The three pain studies targeted postherpetic neuralgia, fibromyalgia, and Hunner-type interstitial cystitis, respectively. According to the company’s announcement and a press release on the same event distributed by Business Wire, participants took ONO-1110 or placebo orally once daily; treatment lasted eight weeks in the first two studies and twelve weeks in the cystitis study. All three studies missed their primary endpoints, meaning they have not provided the evidence of efficacy that the original designs sought to establish.
Trial registry information provides further details on one of the studies. Veeva Clinical Trials lists the postherpetic neuralgia study as completed, with identifiers ONO-1110-04 and NCT06708416 and a total enrollment of 142 participants. The randomized, double-blind, parallel-group study compared ONO-1110 with placebo; participants were Japanese adults with persistent pain at least 90 days after the onset of shingles.
The leads supporting further research came from prespecified subgroup analyses and exploratory post hoc analyses. Ono said these analyses showed signals of improvement in pain measured using a numerical rating scale. However, the announcement has not yet specified which patients showed each signal, the magnitude of improvement, or the statistical details, making it impossible to determine whether the effects are consistent or sufficient to produce a difference patients can perceive. These results may help generate hypotheses for the next round of research, but they cannot overturn the conclusion that the primary endpoints were missed.
On safety, the company said the overall profile was favorable across the five studies, but full adverse event data have not yet been released, and the risks of long-term use cannot be determined from this summary. By comparison, neither the major depressive disorder study nor the social anxiety disorder study showed efficacy signals, so Ono is no longer planning further clinical trials in these two indications.
Ono expects to disclose detailed results at future scientific conferences and through other appropriate channels, and plans follow-up studies in the three pain conditions. The next key question is whether the current analytical leads can be translated into prespecified research questions that can be tested again, and whether new trials can establish which patients benefit and how large those benefits are.